NICE has recommended the first disease-modifying therapy for NHS use to delay the onset of type 1 diabetes, describing it as a first-of-its-kind option that could give some patients extra time before the condition develops. The guidance, published on 23 June 2026, says the therapy may delay the onset of type 1 diabetes for up to three years and will now be made available on the NHS.
A new option for people at risk of type 1 diabetes
The recommendation marks a notable shift in the management of type 1 diabetes, moving beyond treatment after diagnosis to an intervention aimed at postponing the disease itself. NICE said the therapy is intended for NHS use and could provide a meaningful delay in the appearance of symptoms and the need for ongoing diabetes care.
This development follows other recent NICE decisions in conditions and disease, but it stands out because it is focused on altering the course of disease before full onset rather than treating established illness. The recommendation comes as part of a series of June 2026 NHS guidance updates on major conditions, including cancer and diabetes-related care. ([nice.org.uk](https://www.nice.org.uk/news/articles))
Why the decision matters
Type 1 diabetes is a lifelong condition that requires ongoing management once it begins. NICE’s announcement suggests the new therapy may offer patients and clinicians a new way to intervene earlier in the disease pathway. According to NICE, the treatment is the first of its kind to be recommended for NHS use for this purpose, with the potential to delay onset by up to three years. ([nice.org.uk](https://www.nice.org.uk/news/articles))
For health services, the recommendation is likely to attract attention because it opens the door to a preventive approach in a disease that has traditionally been managed after diagnosis. The decision also reflects a broader trend in medicine toward earlier intervention and disease modification, rather than relying solely on symptom control after progression has begun.
Part of a wider wave of NHS guidance
The same NICE news list shows several other recent recommendations, including a new treatment option for recurrent or metastatic cervical cancer on 24 June 2026, and guidance for a pregnancy-specific artificial pancreas for women with type 1 diabetes on 3 June 2026. Those updates indicate continued activity in fast-moving therapeutic areas, especially where NHS access is concerned. ([nice.org.uk](https://www.nice.org.uk/news/articles))
With this latest recommendation, NICE has added a potentially important new tool to the UK’s diabetes care landscape. The next step will be how quickly and widely the NHS can implement the guidance for eligible patients.
For more details, see the NICE news article on the recommendation. ([nice.org.uk](https://www.nice.org.uk/news/articles))
